Emerging degrader technologies engaging lysosomal pathways
Targeted protein degradation (TPD) provides unprecedented opportunities for drug
discovery. While the proteolysis-targeting chimera (PROTAC) technology has already …
discovery. While the proteolysis-targeting chimera (PROTAC) technology has already …
Dementia in Down syndrome: unique insights for Alzheimer disease research
IT Lott, E Head - Nature Reviews Neurology, 2019 - nature.com
Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …
AUTACs: cargo-specific degraders using selective autophagy
D Takahashi, J Moriyama, T Nakamura, E Miki… - Molecular cell, 2019 - cell.com
Protein silencing represents an essential tool in biomedical research. Targeted protein
degradation (TPD) strategies exemplified by PROTACs are rapidly emerging as modalities …
degradation (TPD) strategies exemplified by PROTACs are rapidly emerging as modalities …
Potential protective mechanisms of green tea polyphenol EGCG against COVID-19
Z Zhang, X Zhang, K Bi, Y He, W Yan, CS Yang… - Trends in food science & …, 2021 - Elsevier
Background The world is in the midst of the COVID-19 pandemic. In this comprehensive
review, we discuss the potential protective effects of (−)-epigallocatechin-3-gallate (EGCG) …
review, we discuss the potential protective effects of (−)-epigallocatechin-3-gallate (EGCG) …
Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease
M Perluigi, F Di Domenico… - Physiological …, 2024 - journals.physiology.org
Alzheimer disease (AD) is associated with multiple etiologies and pathological mechanisms,
among which oxidative stress (OS) appears as a major determinant. Intriguingly, OS arises …
among which oxidative stress (OS) appears as a major determinant. Intriguingly, OS arises …
Down syndrome
Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of
clinical features commonly known as Down syndrome (DS). DS is among the most …
clinical features commonly known as Down syndrome (DS). DS is among the most …
Mitochondrial quality surveillance as a therapeutic target in myocardial infarction
Myocardial infarction (MI) is a leading cause of morbidity and mortality worldwide. As
mitochondrial dysfunction critically contributes to the pathogenesis of MI, intensive research …
mitochondrial dysfunction critically contributes to the pathogenesis of MI, intensive research …
Cystathionine-β-synthase: molecular regulation and pharmacological inhibition
Cystathionine-β-synthase (CBS), the first (and rate-limiting) enzyme in the transsulfuration
pathway, is an important mammalian enzyme in health and disease. Its biochemical …
pathway, is an important mammalian enzyme in health and disease. Its biochemical …
Mitochondria can cross cell boundaries: An overview of the biological relevance, pathophysiological implications and therapeutic perspectives of intercellular …
Mitochondria are complex intracellular organelles traditionally identified as the
powerhouses of eukaryotic cells due to their central role in bioenergetic metabolism. In …
powerhouses of eukaryotic cells due to their central role in bioenergetic metabolism. In …
Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome
E Lana-Elola, R Aoidi, M Llorian, D Gibbins… - Science translational …, 2024 - science.org
Down syndrome (DS) is caused by trisomy of human chromosome 21 (Hsa21). DS is a gene
dosage disorder that results in multiple phenotypes including congenital heart defects. This …
dosage disorder that results in multiple phenotypes including congenital heart defects. This …